Companies / CASI Pharmaceuticals, Inc.
CASI Pharmaceuticals, Inc.
CASICIK 895051
Activity
InsidersInstitutions
What the company's own insiders are buying and selling.| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Mar 26, 2021 | WEI-WU HE, Ph.D. CEO | Buy Open-market buy | Common Stock | $6.15M | +3.0M | 3,000,000 | high |
| Aug 19, 2022 | Huang James Director | Buy Open-market buy | Common Stock | $559.4K | +171K | 171,116 | high |
| Aug 18, 2021 | WEI-WU HE, Ph.D. CEO | Buy Open-market buy | Common Stock | $387.0K | +300K +6.40% | 4,983,994 | medium |
| Aug 19, 2021 | WEI-WU HE, Ph.D. CEO | Buy Open-market buy | Common Stock | $226.8K | +180K +3.61% | 5,163,994 | medium |
| Nov 17, 2021 | WEI-WU HE, Ph.D. CEO | Buy Open-market buy | Common Stock | $198.0K | +200K +3.87% | 5,362,569 | medium |
| Nov 18, 2021 | WEI-WU HE, Ph.D. CEO | Buy Open-market buy | Common Stock | $196.0K | +200K +3.73% | 5,558,472 | medium |
| Jun 15, 2022 | WEI-WU HE, Ph.D. CEO | Buy Open-market buy | Common Stock | $159.0K | +50K +8.41% | 644,553 | medium |
| Aug 26, 2022 | Huang James Director | Buy Open-market buy | Common Stock | $148.2K | +40K +16.52% | 278,748 | medium |